Previous 10 | Next 10 |
BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy candidate for the treatment of phenylketonuria (PKU), restored the normal phenylalanine meta...
The FDA has signed off on a Phase 1/2 clinical trial, pheNIX, evaluating Homology Medicines' ( FIXX +0.4% ) gene therapy candidate HMI-102 in adults with a rare inherited disorder called phenylketonuria (PKU), referred to as an inborn error of metabolism. More news on: Homology Medicin...
- Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic - - Initial Clinical Data Expected by the End of 2019 - BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today ...
Homology Medicines (NASDAQ: FIXX ) has filed a sales agreement with Cowen to sell $100M worth of its common stock. More news on: Homology Medicines, Inc., Healthcare stocks news, Read more ...
BEDFORD, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present during a fireside chat at the Alliance for Regenerative Medicine (ARM) Cell & Gene Therapy Investor Day on M...
The following slide deck was published by Homology Medicines, Inc. in conjunction with this Read more ...
Homology Medicines (NASDAQ: FIXX ): Q4 GAAP EPS of -$0.51 misses by $0.07 . Revenue of $0.98M (+19.5% Y/Y) in-line. Press Release More news on: Homology Medicines, Inc., Earnings news and commentary, Healthcare stocks news,
- On Track to Enter the Clinic and Report Initial Data from Phase 1/2 PKU Gene Therapy Trial in 2019 - - New Data Supporting HMI-102 IND Package Demonstrates Reduction of Phe Levels in the Brain and an Increase in Neurotransmitter Metabolism - - Established External and Inte...
BEDFORD, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the Cowen and Company 39th Annual Healthcare Conference on March 12, 2019 at 8:00 a.m. ET at the Boston Marriott C...
OrthoPediatrics (NASDAQ: KIDS ) initiated with Outperform rating and $44 (17% upside) price target at JMP Securities. More news on: OrthoPediatrics Corp., Homology Medicines, Kodiak Sciences, Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Homology Medicines Inc. Company Name:
FIXX Stock Symbol:
NASDAQ Market:
Homology Medicines Inc. Website:
2024-03-25 09:02:02 ET Homology Medicines Inc (FIXX) announced stock split at a ratio of 1-for-18 on 2024-03-25 ... Full story available on KlickAnalytics.com
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstandi...
Homology Medicines has an initial 180-day period through June 26, 2024 to regain compliance with Minimum Bid Price Requirement BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it received notification (“ Nasdaq Notif...